1 Not well-known until recently, this incretin effect is severely reduced in patients with type 2 diabetes (T2DM) and has been therapeutically exploited to develop an entirely new class of antidiabetic drugs
Why they matter: Large randomised cardiovascular and renal outcome trials (EMPA-REG OUTCOME, DAPA-HF, DAPA-CKD, EMPEROR-Reduced/Preserved, CREDENCE, EMPA-KIDNEY) consistently showed reductions in heart-failure hospitalisation, progression of chronic kidney disease, and cardiovascular death
GLP-1 Flex Care with member cash pay Support employees with GLP-1s when appropriate, even without coverage
3.Reconnect with Your Partner: If you are in a committed relationship, the empty nest phase can be an ideal time to nurture and strengthen your bond with your partner
Future Directions Tirzepatide represents just the beginning of multi-agonist approaches
Byetta comes in two dose strengths: 5 micrograms (mcg) and 10 mcg